The Human SARS-CoV-2 Nucleocapsid ELISA quantitates Nucleocapsid in human serum, plasma, or cell culture medium. The assay will exclusively recognize both natural and recombinant Human Nucleocapsid.
Principle of the method
The Human SARS-CoV-2 Nucleocapsid solid-phase sandwich ELISA (enzyme-linked immunosorbent assay) is designed to measure the amount of the target bound between a matched antibody pair. A target-specific antibody has been pre-coated in the wells of the supplied microplate. Samples, standards, or controls are then added into these wells and bind to the immobilized (capture) antibody. The sandwich is formed by the addition of the second (detector) antibody, a substrate solution is added that reacts with the enzyme-antibody-target complex to produce measurable signal. The intensity of this signal is directly proportional to the concentration of target present in the original specimen.
Each manufactured lot of this ELISA kit is quality tested for criteria such as sensitivity, specificity, precision, and lot-to-lot consistency. See manual for more information on validation.
Severe Acute Respiratory Syndrome (SARS), an emerging disease characterized by atypical pneumonia, has recently been attributed to a novel coronavirus (SARS-CoV). The nucleocapsid protein (N) was one of the structural proteins of SARS-CoV (N, S, sE, M). The severe acute respiratory syndrome coronavirus (SARS-CoV) nucleocapsid (N) protein is the most abundant protein in the virus-infected cells. The SARS-CoV-2 S gene has 76% amino acid similarity to the SARS-CoV S gene, and nonsynonymous mutations developed in the S protein as the SARS-CoV epidemic developed, reports have shown that the crystal structure of the SARS-CoV-2 nucleocapsid protein is similar to those of previously described coronavirus N proteins, but their surface electrostatic potential characteristics are distinct.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.